Lexicon Pharmaceuticals LXRX Business Segments — Sales and marketing
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Lexicon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:SellingAndMarketingExpense.
The official record: Lexicon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Lexicon Pharmaceuticals's business segments — sales and marketing.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Lexicon Pharmaceuticals's business segments — sales and marketing?
- Lexicon Pharmaceuticals (LXRX) reported business segments — sales and marketing of $1.08M in Q1 2026.
- How has Lexicon Pharmaceuticals's business segments — sales and marketing changed year-over-year?
- Lexicon Pharmaceuticals's business segments — sales and marketing decreased by 59.6% year-over-year, from $2.67M to $1.08M.
- What is the long-term trend for Lexicon Pharmaceuticals's business segments — sales and marketing?
- Over 3 years (2022 to 2025), Lexicon Pharmaceuticals's business segments — sales and marketing has grown at a -31.6% compound annual growth rate (CAGR), from $19.17M to $6.14M.
- What does business segments — sales and marketing mean?
- Costs incurred to promote, advertise, and distribute the segment's products to customers. This metric captures the investment required to build brand awareness, support product launches, and maintain market share. It is essential for evaluating the efficiency of the segment's commercialization strategy relative to revenue growth.